Famotidine is a Small Molecule owned by Merck & Co, and is involved in 7 clinical trials, which were completed.

Famotidine is a histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.

The revenue for Famotidine is expected to reach a total of $115m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Famotidine NPV Report.

Famotidine is currently owned by Merck & Co. Bausch Health Companies is the other company associated in development or marketing of Famotidine.

Famotidine Overview

Famotidine (Pepcid, Pepcid AC, Gastridin, Motiax, Pepdul, Foxadul, Famotidin, Pepcidine, Pepcidine RPD) is a disubstituted thiazole derivative that acts as an anti-ulcer agent. It is formulated as suspension, tablet, chewable for oral and injection for intravenous administration. Famotidine is indicated for the short-term treatment of active duodenal ulcer in addition to the maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. It is also indicated for the short-term treatment of active benign gastric ulcer and gastroesophageal reflux disease (GERD). Furthermore, it is used for the short-term treatment of esophagitis due to GERD and pathological hypersecretory conditions and heartburn.

Bausch Health Companies Overview

Bausch Health Companies (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.

The company reported revenues of (US Dollars) US$8,434 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 4.6%, compared to an operating margin of 7.7% in FY2020. The net loss of the company was US$948 million in FY2021, compared to a net loss of US$560 million in FY2020. The company reported revenues of US$2,046 million for the third quarter ended September 2022, an increase of 4% over the previous quarter.

Quick View – Famotidine

Report Segments
  • Innovator (NME)
Drug Name
  • Famotidine
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Gastrointestinal
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.